8-K: Acurx Pharmaceuticals Announces 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing

Acurx Pharmaceuticals, a late-stage biopharmaceutical company, announced a 1-for-20 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Acurx Pharmaceuticals, Inc. filed an amendment to its certificate of incorporation to effect a 1-for-20 reverse stock split of its common stock.
• The reverse stock split will become legally effective at 4:01 p.m. Eastern Time on August 4, 2025.
• Shares are expected to begin trading on a post-split basis on The Nasdaq Capital Market at the open of trading on August 5, 2025.
• Every twenty (20) shares of common stock will automatically convert into one (1) share, without changing the par value of $0.001 per share.
• The number of outstanding common shares will be reduced from approximately 30,764,540 shares (as of July 24, 2025) to approximately 1,538,227 shares.
• Proportional adjustments will be made to the exercise price and number of shares for all outstanding stock options, warrants, convertible securities, and shares under stock incentive plans.
• No change will be made to the total number of authorized shares.
• Stockholders entitled to fractional shares will receive a cash payment based on the closing sales price on August 1, 2025.
• The new CUSIP number for the common stock will be 00510M 203.

Sentiment

Score: 3

Explanation: The filing primarily addresses a corporate action (reverse stock split) necessitated by a low share price, which is generally a negative indicator for a company. While it resolves a listing compliance issue, it doesn't reflect positive operational or financial performance. The mention of needing 'appropriate financing' for future clinical trials also points to ongoing financial challenges.

Positives

• The reverse stock split is intended to enable the company to regain compliance with the Nasdaq minimum bid price requirement, preventing potential delisting.

Negatives

• A reverse stock split is typically implemented by companies whose stock price has fallen significantly, indicating poor market performance or investor sentiment.
• The reduction in outstanding shares may not fundamentally change the company's valuation or business prospects without other positive developments.
• The need for a reverse split highlights a challenge in maintaining listing requirements.

Risks

• Uncertainty regarding whether ibezapolstat will benefit from the Qualified Infectious Disease Product (QIDP) designation.
• Risk that ibezapolstat may not advance through the clinical trial process on a timely basis.
• Uncertainty whether clinical trial results for ibezapolstat will be sufficient to warrant submission of marketing approval applications.
• Risk that ibezapolstat may not receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies.
• Risk that ibezapolstat, if approved, may not be successfully distributed and marketed.
• General risks and uncertainties described in the company's annual report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.
• The company's ability to obtain appropriate financing for future clinical trials.

Future Outlook

The company plans to begin international clinical trials for its lead product candidate, ibezapolstat, next year, contingent on securing appropriate financing. It also has preclinical development plans for an oral product candidate for ABSSSI and a parallel program for inhaled anthrax. The reverse stock split is intended to ensure continued listing on Nasdaq.

Management Comments

• Acurx's common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025.
• The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Industry Context

Acurx Pharmaceuticals operates in the biopharmaceutical sector, specifically focusing on developing new antibiotics for difficult-to-treat bacterial infections. The need for a reverse stock split often indicates that a company's stock price has fallen below exchange minimums, a common challenge for smaller biopharma companies that are pre-revenue or in late-stage development, relying heavily on clinical trial success and financing. The focus on Gram-positive selective spectrum antibiotics, particularly for C. difficile and MRSA, addresses a critical unmet medical need given the rise of antibiotic-resistant bacteria.

Comparison to Industry Standards

• The reverse stock split itself is a common corporate action for companies facing delisting from major exchanges due to low share price, a situation not uncommon for small-cap biopharmaceutical companies that are pre-commercialization and highly dependent on R&D milestones and capital raises.
• Many biopharmaceutical companies, such as those developing novel antibiotics, often trade at lower valuations during their clinical development phases until significant positive trial results or regulatory approvals are achieved.
• The company's lead candidate, ibezapolstat, targeting C. difficile infection, is in Phase 3 readiness, which is a critical and capital-intensive stage. Comparable companies with drugs at this stage often face similar financing challenges and stock price volatility.
• The company's strategy to develop Gram-positive selective spectrum (GPSS) antibiotics is a specialized approach within the broader anti-infective market, differentiating it from broader-spectrum antibiotic developers.

Corporate Governance

Stakeholder Impact

• Shareholders: Will see their number of shares reduced by a 1-for-20 ratio, with fractional shares converted to cash. The per-share price is expected to increase proportionally, but the total value of their holdings should remain the same immediately after the split, assuming no market reaction. The primary impact is the potential for continued Nasdaq listing.
• Employees (with stock options/incentives): Their stock options and shares under incentive plans will be proportionally adjusted in terms of exercise price and number of shares, maintaining their intrinsic value.

Next Steps

• Common stock to begin trading on a post-split basis on The Nasdaq Capital Market on August 5, 2025.
• International clinical trials for ibezapolstat are planned to begin next year, subject to obtaining appropriate financing.
• Development program for treatment of inhaled anthrax is being planned in parallel with an oral product candidate for ABSSSI.

Key Dates

Recommendation

While the reverse stock split addresses a critical Nasdaq listing compliance issue, it does not fundamentally alter the company's underlying business or financial health. The company is a late-stage biopharmaceutical firm with a lead candidate (ibezapolstat) that is Phase 3 ready but requires "appropriate financing" for international clinical trials. This indicates ongoing capital needs and inherent risks associated with drug development. The reverse split prevents immediate delisting, which is a positive for current shareholders, but the stock remains speculative, dependent on future clinical success and financing. Therefore, a "hold" recommendation is appropriate for existing investors who understand the high-risk, high-reward nature of biopharma, while new investors might wait for more definitive clinical or financing news.

Keywords

Acurx Pharmaceuticals, ACXP, Reverse Stock Split, Nasdaq Compliance, Biopharmaceutical, Antibiotics, Ibezapolstat, C. difficile Infection, Clinical Trials, Stock Market, Corporate Action, Share Consolidation